346 results on '"Coso D"'
Search Results
2. Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation
3. Feasibility of High Dose Melphalan (140 mg/m2) and Peripheral Blood Stem Cell Support as Consolidation for Patients over 60 Years with Acute Myeloid Leukemia in First Complete Remission
4. Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas
5. Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity
6. Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT
7. Lymphomes B primitifs du médiastin : aspect clinique
8. Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available
9. Correction: Corrigendum: Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT
10. Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT
11. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin’s lymphoma
12. EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL
13. Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donors
14. Automated washing of autologous hematopoietic stem cell grafts after thawing does not impair engraftment
15. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma
16. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study
17. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma
18. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison
19. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation
20. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation
21. Traitement précoce de l’anémie, en cours de chimiothérapie, par érythropoïétine : qu’attendre d’un schéma simplifié? À propos de l’expérience de l’Institut Paoli Calmettes-Marseille
22. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen
23. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon α-2b for the treatment of chronic myelogenous leukemia patients in chronic phase
24. Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single center
25. A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients
26. Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high–intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin’s lymphoma: an oligocentric report on 42 patients
27. Impact of prior autologous mobilization status on engraftment and outcome after allogeneic stem cell transplantation for lymphoma and myeloma: P529
28. Pre-transplant rituximab is associated with reduced rate of acute GvHD after RIC-AlloSCT in lymphoma patients: P493
29. Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a ‘donor’ versus ‘no donor’ comparison
30. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer
31. Autologous stem cell transplantation in elderly patients with multiple myeloma: age per se does not affect outcome: O163
32. A case of rituximab-related urticarial reaction in cutaneous B-cell lymphoma
33. Reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukaemia: long-term results of a "donor" versus "no donor" comparison
34. Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission
35. Platelets recovery and transfusion needs after reduced-intensity conditioning allogeneic stem cell transplantation
36. The "cytokine storm" at the era of reduced-intensity conditioning allogeneic stem cell transplantation
37. The role of reduced-intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukaemia: a donor versus no donor comparison
38. Monoclonal antibodies and cytomegalovirus infections
39. Clinical outcome after front-line intensive sequential chemotherapy (ISC) in patients with aggressive non-Hodgkin's lymphoma and high-risk international prognostic index (IPI 3): Final analysis of survival in two consecutive ISC trials
40. Erratum: Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available
41. Clinical and biological aspects of aggressive B-cell non-Hodgkin lymphoma in adolescents and young adults
42. Erratum: Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas
43. A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB (R²) COMBINATION IN PATIENTS WITH HIGH-RISK REFRACTORY/RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA
44. A cyclophosphamide-induced autoimmune diabetes
45. Erratum: Reduced-intensity conditioning regimen with in vivo T-cell depletion for patients with haematological malignancies: results using unrelated and sibling donors
46. Amylose AL et maladie kystique pulmonaire : une association rare
47. Neuroprotective Effects of Selected Microbial-Derived Phenolic Metabolites and Aroma Compounds from Wine in Human SH-SY5Y Neuroblastoma Cells and Their Putative Mechanisms of Action
48. A conditioning platform based on fludarabine, busulfan and two days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor
49. Understanding the protective effects of wine components and their metabolites in the brain function
50. Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.